Protara Therapeutics, Inc. - ROE
TARA
Price:
$3.98
Market Cap:
$153.59M
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, I...[Read more]
Industry
Biotechnology
IPO Date
2014-10-22
Stock Exchange
NASDAQ
Ticker
TARA
PE Ratio
[-2.93]
ROE
[-38.70%]
Current Ratio
[15.69]
Dividend Yield
[0%]
Enterprise Value
[141.91M]
Dividend History
The ROE as of June 2026 (TTM) for Protara Therapeutics, Inc. (TARA) is -38.70%
According to Protara Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -38.70%. This represents a change of 296.87% compared to the average of -9.75% of the last 4 quarters.
Protara Therapeutics, Inc. (TARA) Historical ROE (quarterly & annually)
How has TARA ROE performed in the past?
The mean historical ROE of Protara Therapeutics, Inc. over the last ten years is -74.54%. The current -38.70% ROE has changed -48.08% with respect to the historical average. Over the past ten years (40 quarters), TARA's ROE was at its highest in in the December 2019 quarter at 40.44%. The ROE was at its lowest in in the December 2022 quarter at -38.17%.
Average
-74.54%
Median
-61.88%
Minimum
-234.54%
Maximum
-17.05%
Protara Therapeutics, Inc. (TARA) ROE by Quarter and Year
Discovering the peaks and valleys of Protara Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 121.38%
Maximum Annual ROE = -17.05%
Minimum Annual Increase = -92.73%
Minimum Annual ROE = -234.54%
| Year | ROE | Change |
|---|---|---|
| 2025 | -29.24% | 9.60% |
| 2024 | -26.68% | -54.90% |
| 2023 | -59.16% | -8.43% |
| 2022 | -64.61% | 121.38% |
| 2021 | -29.18% | 71.13% |
| 2020 | -17.05% | -92.73% |
| 2019 | -234.54% | 88.50% |
| 2018 | -124.43% | 44.26% |
| 2017 | -86.25% | 16.23% |
| 2016 | -74.21% | 120.10% |
Protara Therapeutics, Inc. (TARA) Average ROE
How has TARA ROE performed in the past?
The current ROE of Protara Therapeutics, Inc. (TARA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-38.36%
5-year avg
-41.78%
10-year avg
-74.54%
Protara Therapeutics, Inc. (TARA) ROE vs. Peers
How is TARA’s ROE compared to its peers?
Protara Therapeutics, Inc.’s ROE is less than Neonc Technologies Holdings, Inc. (284.28%), greater than Genfit S.A. (-596.44%), greater than Invivyd, Inc. (-53.48%), greater than Codexis, Inc. (-68.09%), greater than MediWound Ltd. (-67.22%), greater than SELLAS Life Sciences Group, Inc. (-47.12%), greater than OmniAb, Inc. (-20.31%), greater than Orchestra BioMed Holdings, Inc. (-137.99%), less than Sangamo Therapeutics, Inc. (6.69%), greater than Prelude Therapeutics Incorporated (-118.24%),
| Company | ROE | Market cap |
|---|---|---|
| 284.28% | $105.37M | |
| -596.44% | $445.68M | |
| -53.48% | $128.73M | |
| -68.09% | $233.60M | |
| -67.22% | $154.68M | |
| -47.12% | $1.15B | |
| -20.31% | $278.67M | |
| -137.99% | $238.92M | |
| 6.69% | $70.43M | |
| -118.24% | $245.95M |
Build a custom stock screener for Protara Therapeutics, Inc. (TARA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Protara Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Protara Therapeutics, Inc. (TARA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Protara Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Protara Therapeutics, Inc.'s ROE?
How is the ROE calculated for Protara Therapeutics, Inc. (TARA)?
What is the highest ROE for Protara Therapeutics, Inc. (TARA)?
What is the 3-year average ROE for Protara Therapeutics, Inc. (TARA)?
What is the 5-year average ROE for Protara Therapeutics, Inc. (TARA)?
How does the current ROE for Protara Therapeutics, Inc. (TARA) compare to its historical average?